C3 Glomerulopathy clinical trials

Explore recruiting c3 glomerulopathy clinical trials.

Recruiting c3 glomerulopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

C3 Glomerulopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis

Germany, France, Czechia, Netherlands, Greece, Italy +1 more

Phase III and phase IV (Integrated) EU CTIS Study details

Phase 2, multicenter, randomized, open-label, controlled, 2-arm cross-over study to evaluate the clinical efficacy and safety of a renin inhibitor, aliskiren, compared to an angiotensin converting enzyme inhibitor, enalapril, in children and adults with C3 glomerulopathy

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3glomerulopathy

Germany, France, Spain, Slovakia, Netherlands, Greece +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients with C3-Glomerulopathy

Austria, Greece, Spain, Czechia, Latvia, Belgium +5 more

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)

France, Italy, Spain, Germany

Therapeutic use (Phase IV) EU CTIS Study details

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)

Spain, Italy, Czechia, France, Netherlands, Belgium +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

C3 Glomerulopathy trials by city

C3 Glomerulopathy in Toronto C3 Glomerulopathy in Vancouver C3 Glomerulopathy in Montreal C3 Glomerulopathy in Calgary C3 Glomerulopathy in Edmonton C3 Glomerulopathy in Ottawa C3 Glomerulopathy in Winnipeg C3 Glomerulopathy in Quebec City C3 Glomerulopathy in Hamilton C3 Glomerulopathy in Kitchener C3 Glomerulopathy in London C3 Glomerulopathy in Halifax C3 Glomerulopathy in New York C3 Glomerulopathy in Los Angeles C3 Glomerulopathy in Chicago C3 Glomerulopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease